refractory chronic cough
Conditions
Interventions
Mirogabalin:Mirogabalin
Sponsors
Tongji Hospital of Tongji University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age > 18 years; 2. Cough as the sole or predominant symptom, duration > 8 weeks, with no significant abnormalities on chest CT; 3. Cough Visual Analogue Scale (VAS) score = 40mm; 4. According to the "Guidelines for the Diagnosis and Management of Cough (2021)", chronic cough remains unexplained after recommended standardized investigations and treatment; or chronic cough that persists despite empirical treatment targeting known etiologies of chronic cough; or chronic cough where there is evidence of an etiology but treatment response is poor and cough persists; 5. Signed informed consent form.
Exclusion criteria
Exclusion criteria: 1. Current smokers or those who quit smoking less than 2 years ago; 2. History of respiratory tract infection within the past 8 weeks; 3. Pregnant or lactating women; 4. Use of angiotensin-converting enzyme inhibitors (ACEI) within the past 3 months or requiring long-term ACEI therapy; 5. Contraindication or allergy to the study drugs; 6. Comorbid severe cardiovascular disease, hepatic or renal insufficiency, neurological disorders, mental illness or drug dependence, hearing or communication impairment; 7. Any other condition deemed by the investigator to be unsuitable for trial participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cough resolution rate ar 10 week; | — |
Secondary
| Measure | Time frame |
|---|---|
| Hull Airway Reflux Questionnaire (HARQ) score;Leicester Cough Questionnaire (LCQ) score;GerdQ questionnaire score;Capsaicin cough threshold;Cough Evaluation Test (CET) score;Cough Visual Analogue Scale (VAS) score; | — |
Countries
China
Contacts
Public ContactYu Li
Tongji Hospital of Tongji University
Outcome results
None listed